Anacor Pharmaceuticals, Inc. Announces Second Development Candidate in Animal Health Under Research Collaboration With Eli Lilly and Company

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it has achieved its second development candidate in its animal health collaboration with Eli Lilly and Company (Lilly). Anacor’s research collaboration with Lilly is focused on the use of Anacor’s boron chemistry to discover products for a variety of animal health applications. Under the terms of the collaboration, Anacor will receive a $1 million payment for achieving this milestone. Anacor and Lilly achieved the first development candidate under this collaboration in August 2011.